Filing Flows › Adma Biologics (ADMA) › R&D spending
Adma Biologics (ADMA) R&D spending by quarter
Adma Biologics' R&D spending was $4.5M in Q3 2026 (third quarter 2026), -25% from Q2 2026. Over the last 6 quarters it ranged from $826K (Q1 2025) to $6.0M (Q2 2026).
| Quarter | R&D spending | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $4.5M | -25% | +194% |
| Q2 2026 | $6.0M | +337% | +483% |
| Q4 2025 | $1.4M | -10% | — |
| Q3 2025 | $1.5M | +48% | — |
| Q2 2025 | $1.0M | +25% | — |
| Q1 2025 | $826K | — | — |
Q3 2026 at a glance
Adma Biologics, Q3 2026: revenue $141M (+5% year over year), operating margin 48.0%, net earnings $49.9M, operating cash flow $17.4M. The chart follows the revenue to costs, profit and cash.
Questions
What is Adma Biologics' R&D spending?
Adma Biologics' R&D spending was $4.5M in Q3 2026 (third quarter 2026), -25% from Q2 2026.
How has Adma Biologics' R&D spending changed?
Over the last 6 quarters it ranged from $826K (Q1 2025) to $6.0M (Q2 2026).